Please try another search
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.
Name | Age | Since | Title |
---|---|---|---|
Ragupathy Madiyalakan | - | 2004 | CEO & Director |
Ki-Jun Hwang | - | 2005 | Member of Scientific Advisory Board |
Lorne T. Meikle | - | 2023 | Chairman |
Christopher Nicodemus | - | 2010 | Chairman of Scientific Advisory Board |
William John Meekison | 58 | 2023 | Director |
John Mark Lievonen | - | 2021 | Independent Director |
Jeffrey Shon | - | 2021 | Independent Director |
Ronald Moore | - | 2005 | Member of Scientific Advisory Board |
Michael A. Hollingsworth | - | - | Member of Scientific Advisory Board |
Norma Beauchamp | 61 | 2023 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review